Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2018

01-07-2018 | Original Article

Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma

Authors: Jung-Soo Pyo, Joo Heon Kim

Published in: Pathology & Oncology Research | Issue 3/2018

Login to get access

Abstract

The aim of this study was to elucidate the clinicopathological characteristics of the micropapillary (MP) subtype and its correlation with survival in lung adenocarcinoma. We investigated the clinicopathological characteristics, including the incidence, sex, smoking history, tumor size, lymph node metastasis, lymphovascular invasion, distant metastasis, genetic alteration, and prognosis in lung adenocarcinoma with the MP pattern through a meta-analysis. From 48 eligible studies, 19,502 lung adenocarcinomas were included. The incidence rate of the MP pattern was 0.101 [95% confidence interval (CI) 0.075–0.136]. There was no significant difference between stage I and III tumors. Lung adenocarcinoma with the MP pattern showed higher rates of lymphatic invasion (0.526, 95% CI 0.403–0.645). MP pattern was found in 0.150 (95% CI 0.008–0.790) of lung adenocarcinoma with distant metastasis. In lung adenocarcinoma with the MP pattern, the estimated rates of ALK, EGFR, and KRAS mutations were 0.102 (95% CI 0.027–0.322), 0.620 (95% CI 0.444–0.769), and 0.118 (95% CI 0.027–0.393), respectively. The MP pattern of lung adenocarcinoma was significantly correlated with worse overall and disease-free survival rates (hazard ratio 1.704, 95% CI 1.216–2.387, and 2.082, 95% CI 1.541–2.813, respectively). Taken together, identification of the MP pattern in lung adenocarcinoma is useful for prediction of clinicopathological characteristics and prognosis of patients.
Literature
1.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart, 4th edn. International Agency for Research on Cancer, Lyon
2.
Travis WD, Brambilla E, Nicholson AG et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260CrossRefPubMed
3.
Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4:127ps10CrossRefPubMed
4.
Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG et al (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging basedon analysis of 514 stage I cases. Mod Pathol 24:653–664CrossRefPubMed
5.
Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA (2011) Does lung adenocarcinoma subtype predict patient survival?: aclinicopathologic study based on the new international Association for theStudy of lung cancer/American Thoracic Society/European RespiratorySociety international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6:1496–1504CrossRefPubMed
6.
Warth A, Muley T, Meister M et al (2012) The novel histologic International Association for the Study of LungCancer/American Thoracic Society/European Respiratory Society classificationsystem of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446CrossRefPubMed
7.
Cai YR, Dong YJ, Wu HB et al (2016) Micropapillary: a component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas. Sci Rep 6:23755CrossRefPubMedPubMedCentral
8.
Amin MB, Tamboli P, Merchant SH et al (2002) Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 26:358–364CrossRefPubMed
9.
Sánchez-Mora N, Presmanes MC, Monroy V et al (2008) Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol 39:324–330CrossRefPubMed
10.
Makimoto Y, Nabeshima K, Iwasaki H et al (2005) Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology 46:677–684CrossRefPubMed
11.
Miyoshi T, Satoh Y, Okumura S et al (2003) Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 27:101–109CrossRefPubMed
12.
Motoi N, Szoke J, Riely GJ et al (2008) Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32:810–827CrossRefPubMed
13.
Roh MS, Lee JI, Choi PJ, Hong YS (2004) Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma. Histopathology 45:580–586CrossRefPubMed
14.
Furukawa M, Toyooka S, Ichimura K et al (2016) Genetic alterations in lung adenocarcinoma with a micropapillary component. Mol Clin Oncol 4:195–200CrossRefPubMed
15.
Bao F, Yuan P, Yuan X, Lv X, Wang Z, Hu J (2014) Redictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer. J Thorac Dis 6:1697–1703PubMedPubMedCentral
16.
Cha MJ, Lee HY, Lee KS et al (2014) Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg 147:921–928.e2CrossRefPubMed
17.
Gu J, Lu C, Guo J et al (2013) Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-a single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol 107:474–480CrossRefPubMed
18.
Hirano H, Maeda H, Takeuchi Y et al (2014) Lymphatic invasion of micropapillary cancer cells is associated with a poor prognosis of pathological stage IA lung adenocarcinomas. Oncol Lett 8:1107–1111CrossRefPubMedPubMedCentral
19.
Hung JJ, Jeng WJ, Wu YC, Chou TY, Hsu WH (2016) Factors predicting organ-specific distant metastasis in patients with completely resected lung adenocarcinoma. Oncotarget 7:58261–58273PubMedPubMedCentral
20.
Kadota K, Nitadori J, Sarkaria IS et al (2013) Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer 119:931–938CrossRefPubMed
21.
Kamiya K, Hayashi Y, Douguchi J et al (2008) Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 21:992–1001CrossRefPubMed
22.
Kawakami T, Nabeshima K, Makimoto Y et al (2007) Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors. Mod Pathol 20:514–521CrossRefPubMed
23.
Kawakami T, Nabeshima K, Hamasaki M, Iwasaki A, Shirakusa T, Iwasaki H (2009) Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas. Virchows Arch 454:61–70CrossRefPubMed
24.
Koga K, Hamasaki M, Kato F et al (2013) Association of c-met phosphorylation with micropapillary pattern and small cluster invasion in pT1-size lung adenocarcinoma. Lung Cancer 82:413–419CrossRefPubMed
25.
Lee G, Lee HY, Jeong JY et al (2015) Clinical impact of minimal micropapillary pattern in invasive lung adenocarcinoma: prognostic significance and survival outcomes. Am J Surg Pathol 39:660–666CrossRefPubMed
26.
Li H, Pan Y, Li Y et al (2013) Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 79:8–13CrossRefPubMed
27.
Lu F, Li S, Dong B, Zhang S, Lv C, Yang Y (2016) Identification of lung adenocarcinoma mutation status based on histologic subtype: retrospective analysis of 269 patients. Thorac Cancer 7:17–23CrossRefPubMed
28.
Luo J, Huang Q, Wang R et al (2016) Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB. J Cancer Res Clin Oncol 142:2031–2040CrossRefPubMed
29.
Maeda R, Isowa N, Onuma H et al (2009) Lung adenocarcinomas with micropapillary components. Gen Thorac Cardiovasc Surg 57:534–539CrossRefPubMed
30.
Mäkinen JM, Laitakari K, Johnson S et al (2015) Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma. Lung Cancer 90:568–574CrossRefPubMed
31.
Ninomiya H, Hiramatsu M, Inamura K et al (2009) Orrelation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 63:235–240CrossRefPubMed
32.
Nishino M, Klepeis VE, Yeap BY et al (2012) Istologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol 25:1462–1472CrossRefPubMed
33.
Nitadori J, Bograd AJ, Kadota K et al (2013) Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst 105:1212–1220CrossRefPubMedPubMedCentral
34.
Ohe M, Yokose T, Sakuma Y et al (2012) Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol 7:3CrossRefPubMedPubMedCentral
35.
Onozato ML, Kovach AE, Yeap BY et al (2013) Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol 37:287–294CrossRefPubMedPubMedCentral
36.
Russell PA, Barnett SA, Walkiewicz M et al (2013) Orrelation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol 8:461–468CrossRefPubMed
37.
Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y (2013) Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol 30:645CrossRefPubMed
38.
Sumiyoshi S, Yoshizawa A, Sonobe M et al (2013) Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer 81:53–59CrossRefPubMed
39.
Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L (2014) Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol 12:148CrossRefPubMedPubMedCentral
40.
Tsutsumida H, Nomoto M, Goto M et al (2007) A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein a expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 20:638–647CrossRefPubMed
41.
Wang L, Jiang W, Zhan C et al (2015) Lymph node metastasis in clinical stage IA peripheral lung cancer. Lung Cancer 90:41–46CrossRefPubMed
42.
Warth A, Penzel R, Lindenmaier H et al (2014) EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur Respir J 43:872–883CrossRefPubMed
43.
Yanagawa N, Shiono S, Abiko M, Katahira M, Osakabe M, Ogata SY (2016) The clinical impact of solid and Micropapillary patterns in resected lung adenocarcinoma. J Thorac Oncol 11:1976–1983CrossRefPubMed
44.
Yang F, Chen K, Liao Y et al (2014) Risk factors of recurrence for resected T1aN0M0 invasive lung adenocarcinoma: a clinicopathologic study of 177 patients. World J Surg Oncol 12:285CrossRefPubMedPubMedCentral
45.
Yang X, Liu Y, Lian F et al (2014) Lepidic and micropapillary growth pattern and expression of Napsin a can stratify patients of stage I lung adenocarcinoma into different prognostic subgroup. Int J Clin Exp Pathol 7:1459–1468PubMedPubMedCentral
46.
Ye B, Cheng M, Li W et al (2014) Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 98:217–223CrossRefPubMed
47.
Yeh YC, Wu YC, Chen CY, Wang LS, Hsu WH, Chou TY (2012) Stromal invasion and micropapillary pattern in 212 consecutive surgically resected stage I lung adenocarcinomas: histopathological categories for prognosis prediction. J Clin Pathol 65:910–918CrossRefPubMed
48.
Yoshiya T, Mimae T, Tsutani Y et al (2016) Prognostic role of subtype classification in small-sized pathologic N0 invasive lung adenocarcinoma. Ann Thorac Surg 102:1668–1673CrossRefPubMed
49.
Yu Y, Ding Z, Jian H, Shen L, Zhu L, Lu S (2016) Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma. Cancer Med 5:2323–2331CrossRefPubMedPubMedCentral
50.
Yu Y, Ding Z, Zhu L, Teng H, Lu S (2016) Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. Spring 5:894CrossRef
51.
Zhang J, Liang Z, Gao J, Luo Y, Liu T (2011) Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology 59:1204–1214CrossRefPubMed
52.
Zhang Y, Wang R, Cai D et al (2014) A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol 9:1772–1778CrossRefPubMed
53.
Zhang Y, Sun Y, Xiang J, Zhang Y, Hu H, Chen H (2014) A clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancer. J Thorac Cardiovasc Surg 148:1193–1199CrossRefPubMed
54.
Zhao Y, Wang R, Shen X et al (2016) Minor components of Micropapillary and solid subtypes in lung adenocarcinoma are predictors of lymph node metastasis and poor prognosis. Ann Surg Oncol 23:2099–2105CrossRefPubMedPubMedCentral
55.
Zhao ZR, Xi SY, Li W et al (2015) Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma. Lung Cancer 90:604–609CrossRefPubMed
56.
Parmar MK, Torri V (1998) Stewart L (1998) extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834CrossRefPubMed
57.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335–371CrossRefPubMed
58.
Yanagawa N, Shiono S, Abiko M et al (2014) The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg 98:453–458CrossRefPubMed
59.
De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA (2009) Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol 131:694–700CrossRefPubMed
60.
Tsao MS, Marguet S, Le Teuff G et al (2015) Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 33:3439–3446CrossRefPubMedPubMedCentral
Metadata
Title
Clinicopathological Significance of Micropapillary Pattern in Lung Adenocarcinoma
Authors
Jung-Soo Pyo
Joo Heon Kim
Publication date
01-07-2018
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0274-7

Other articles of this Issue 3/2018

Pathology & Oncology Research 3/2018 Go to the issue

Original Article

Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study

Original Article

MiR-16-1 Targeted Silences Far Upstream Element Binding Protein 1 to Advance the Chemosensitivity to Adriamycin in Gastric Cancer

Original Article

Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT

Erratum

Erratum to: TERT Promoter Mutation and Telomere Length in Salivary Gland Tumors

Original Article

Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps

Original Article

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits